PSS10 A COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE AND SEVERE PSORIASIS IN MEXICO (Englisch)

In: VALUE IN HEALTH   ;  14 ,  3  ;  A55  ;  2011
  • ISSN:
    1098-3015
  • Aufsatz (Zeitschrift)  /  Print

Wie erhalte ich diesen Titel?

© Metadata Copyright the British Library Board and other contributors. All rights reserved.

Inhaltsverzeichnis – Band 14, Ausgabe 3

Zeige alle Jahrgänge und Ausgaben

Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.

1
Systematic Screening for Chlamydia trachomatis: Estimating Cost-Effectiveness Using Dynamic Modeling and Dutch Data
de Vries, R. / van Bergen, J. E. / de Jong-van den Berg, L. T. / Postma, M. J. | 2006
1
Beyond AWP . . . Way Beyond
Willke, R. J. | 2010
1
Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive
Valentine, W. J. / Tucker, D. / Palmer, A. J. / Minshall, M. E. / Foos, V. / Silberman, C. | 2009
1
Cost-Effectiveness of Nonpharmacologic, Nonsurgical Interventions for Hip and/or Knee Osteoarthritis: Systematic Review
Pinto, D. / Robertson, M. C. / Hansen, P. / Abbott, J. H. | 2012
1
Estimates of Costs of Hospital Stay for Variceal and Nonvariceal Upper Gastrointestinal Bleeding in the United States
Viviane, A. / Alan, B. N. | 2008
1
A I-Year Cost-Effectiveness Model for the Treatment of Chronic Schizophrenia with Acute Exacerbations in Belgium
Lecomte, P. / De Hert, M. / van Dijk, M. / Nuitjen, M. / Nuyts, G. / Persson, U. | 2000
1
Renewal of our Value in Health Mission and Policy As We Enter Our Fourth Year
| 2001
1
Cardioverter Defibrillators in Primary Prevention of Sudden Cardiac Death: A Cost or an Investment?:
Boriani, G. | 2007
1
Probabilistic Analysis of Cost-Effectiveness Models: Statistical Representation of Parameter Uncertainty
Briggs, A. | 2005
1
Turning the Spotlight on Experimental Design in Discrete Choice Experiments—A Focus on Pragmatic Approaches in Health
Whitty, J. A. / Kauf, T. L. | 2013
1
The use of instrumental variables: An alternative to traditional modeling?
Neyt, M. / Van Brabandt, H. / De Laet, C. | 2011
1
Proposal of Polish Guidelines for Conducting Financial Analysis and Their Comparison to Existing Guidance on Budget Impact in Other Countries
Orlewska, E. / Mierzejewski, P. | 2004
1
Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force
Thokala, P. / Devlin, N. / Marsh, K. / Baltussen, R. / Boysen, M. / Kalo, Z. / Longrenn, T. / Mussen, F. / Peacock, S. / Watkins, J. | 2016
1
The Value Of Economic Modeling Studies in the Evaluation of Treatment Strategies for Multiple Sclerosis
Detournay, B. / Cemka-Eval Team | 2002
1
Can We Use Social Media to Support Content Validity of Patient-Reported Outcome Instruments in Medical Product Development?
Rothman, M. / Gnanaskathy, A. / Wicks, P. / Papadopoulos, E. J. | 2015
1
Medical Nutrition Terminology and Regulations in the United States and Europe—A Scoping Review: Report of the ISPOR Nutrition Economics Special Interest Group
Freijer, Karen / Volger, Sheri / Pitter, János G. / Molsen-David, Elizabeth / Cooblall, Clarissa / Evers, Silvia / Hiligsmann, Mickaël / Danel, Aurelie / Lenoir-Wijnkoop, Irene | 2019
1
Review: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
Goettsch, W. G. / Enzing, J. | 2014
1
Value in Health: "Bridging the Gap" Among Our Disciplines
Mauskopf, J. | 2003
1
Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials
Papp, Kim A. / Yang, Min / Sundaram, Murali / Jarvis, John / Betts, Keith A. / Bao, Yanjun / Signorovitch, James E. | 2018
2
What's in a Perspective?
Glick, H. A. | 2010
3
A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases:
Peterson, A. M. / Nau, D. P. / Cramer, J. A. / Benner, J. / Gwadry-Sridhar, F. / Nichol, M. | 2007
3
Making Decisions on Technology Availability in the British National Health Service-Why We Need Reliable Models
Akehurst, R. L. | 2003
3
ISPOR Inaugural European Conference: An Overview
Rindress, D. | 1999
3
Growth and Quality of the Cost-Utility Literature, 1976-2001
Neumann, P. J. / Greenberg, D. / Olchanski, N. V. / Stone, P. W. / Rosen, A. B. | 2005
3
Outcomes Research in the Health-Care System: Driven by Results Ken Shermock PharmD
The Cleveland Clinic Foundation | 2002
3
Can we account for selection bias? A comparison between bare metal and drug-eluting stents
De Ridder, A. / De Graeve, D. | 2011
3
Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force
Reed Johnson, F. / Lancsar, E. / Marshall, D. / Kilambi, V. / M&#x000FC / hlbacher, A. / Regier, D. A. / Bresnahan, B. W. / Kanninen, B. / Bridges, J. F. | 2013
3
Improving the Usefulness of Budget Impact Analyses: A U.S. Payer Perspective
Watkins, J. B. / Danielson, D. | 2014
3
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report-Part I
Hay, J. W. / Smeeding, J. / Carroll, N. V. / Drummond, M. / Garrison, L. P. / Mansley, E. C. / Mullins, C. D. / Mycka, J. M. / Seal, B. / Shi, L. | 2010
4
Cost-Effectiveness of Pemetrexed Plus Cisplatin: Malignant Pleural Mesothelioma Treatment in UK Clinical Practice
Cordony, A. / Le Reun, C. / Smala, A. / Symanowski, J. T. / Watkins, J. | 2008
5
Identifying Initial Diagnosis in Database Research
| 1999
5
Budget Impact Analysis�Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
Sullivan, S. D. / Mauskopf, J. A. / Augustovski, F. / Jaime Caro, J. / Lee, K. M. / Minchin, M. / Orlewska, E. / Penna, P. / Rodriguez Barrios, J. M. / Shau, W. Y. | 2014
5
US Regulation of Pharmaceutical Outcomes Research
Burke, L. B. | 2001
5
Review of Legislation Relating to Promotion of Medicinal Products in the European Union - Are Health Economics Data Covered?
| 1999
5
The Economics of Gene Therapy and of Pharmacogenetics
Danzon, P. / Towse, A. | 2002
5
Applying Dynamic Simulation Modeling Methods in Health Care Delivery Research—The SIMULATE Checklist: Report of the ISPOR Simulation Modeling Emerging Good Practices Task Force
Marshall, D. A. / Burgos-Liz, L. / IJzerman, M. J. / Osgood, N. D. / Padula, W. V. / Higashi, M. K. / Wong, P. K. / Pasupathy, K. S. / Crown, W. | 2015
6
A New Method for Expressing Survival and Life Expectancy in Cancer Patients
| 1999
6
How Do Patients Make Satisfaction Judgments? Answers from Structural Equation Modeling
| 1999
6
The ISPOR Good Practice Modeling Principles-A Sensible Approach: Be Transparent, Be Reasonable
Garrison, L. P. | 2003
6
Cost-Effectiveness Analysis of High-Dose Chemotherapy with Hematopoietic Rescue as Primary Treatment for Metastatic Breast Cancer
| 1999
7
An 11-Year, Controlled Study of Healthcare Resource Use and Mortality for Patients with Parkinson's Disease
| 1999
7
Practice Patterns of Chemotherapy Usage and Associated Neutropenia and Febrile Neutropenia (FN) in Europe
| 1999
8
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report-Part II
Garrison, L. P. / Mansley, E. C. / Abbott, T. A. / Bresnahan, B. W. / Hay, J. W. / Smeeding, J. | 2010
8
Pharmaceutical Regulation: The Early Experience of the NHS National Institute for Clinical Excellence (NICE) Appraisal Process-Where Are We Headed?
Taylor, R. | 2001
8
Economic Evaluation of Acamprosate in Maintaining Abstinence in Alcohol-Dependent Patients
| 1999
8
Cross-Cultural Adaptation of the Migraine-Specific Quality of Life Questionnaire (MSQ) in 14 Languages
| 1999
8
Cost-Utility Analysis of Laparoscopic versus Open Surgery for Colonic Disease
| 1999
9
Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies
Weinstein, M. C. / O Brien, B. / Hornberger, J. / Jackson, J. / Johannesson, M. / McCabe, C. / Luce, B. R. | 2003
9
The Effect of an Open Access Endoscopy Service on Prescribing Costs of Ulcer-Healing Drugs
| 1999
9
DIGEST International Survey: Impact of Upper Gastrointestinal Symptoms on Resource Utilization and Quality of Life
| 1999
9
Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non–Small Cell Lung Cancer
Hashim, Mahmoud / Pfeiffer, Boris M. / Bartsch, Robert / Postma, Maarten / Heeg, Bart | 2018
10
Compliance with Inhaled Corticosteroids and Hospitalization for Asthma
| 1999
10
Quality of Life of Asthma Patients Relative to Asthma Severity
| 1999
10
Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability
Barbieri, M. / Drummond, M. / Willke, R. / Chancellor, J. / Jolain, B. / Towse, A. | 2005
10
Effectiveness of Oral Ciprofloxacin in the Treatment of Exacerbations of Chronic Airway Diseases
| 1999
10
Cost-Effectiveness of Treatments Reducing Coronary Heart Disease Mortality in Ireland, 2000 to 2010
Bennett, K. / Kabir, Z. / Barry, M. / Tilson, L. / Fidan, D. / Shelley, E. / Capewell, S. | 2009
11
Cross-Cultural Adaptation of the Pediatric Asthma Caregiver Quality of Life Questionnaire (PACQLQ) in 19 Countries
| 1999
11
Is Trimethoprim Resistance an Outcome of Community Antibiotic Prescribing?
| 1999
11
Outcomes Research in Health Care: Simulations to Drive Cost Conclusions
Frear, R. / Motheral, B. | 2004
12
Preliminary Quality-of-Life Evaluation of the German SAT Trial: Comparison of SF-36, EuroQol, Time Trade-Off Method, and Willingness to Pay Method
| 1999
12
Cost-Effectiveness of Treating High-Risk Individuals, Aged 45-65, with Statins in Germany for Primary and Secondary Prevention of Coronary Heart Disease
| 1999
12
Ciprofloxacin Is More Successful and Cost-Effective than Trimethoprim/Sulfamethoxazole in the Oral Ambulatory Treatment of Women with Uncomplicated Acute Pyelonephritis
| 1999
12
Economic Evaluation of Voriconazole versus Conventional Amphotericin B in the Treatment of Invasive Aspergillosis in Germany
Jansen, J. P. / Kern, W. V. / Cornely, O. A. / Karthaus, M. / Ruhnke, M. / Ullmann, A. J. / Resch, A. | 2006
12
Regulation of Pharmacoeconomics and Outcomes Research
Radensky, P. | 2001
12
Evaluation of Therapeutic Strategies: A New Method for Balancing Risk and Benefit
Troche, C. J. / Paltiel, A. D. / Makuch, R. W. | 2000
13
The Role of the Expected Value of Individualized Care in Cost-Effectiveness Analyses and Decision Making
van Gestel, A. / Grutters, J. / Schouten, J. / Webers, C. / Beckers, H. / Joore, M. / Severens, J. | 2012
13
Improved Myocardial Protection during Coronary Bypass Surgery Shortens Hospital Stay and Saves Costs
| 1999
13
Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA
Kristensen, Finn Børlum / Husereau, Don / Huić, Mirjana / Drummond, Michael / Berger, Marc L. / Bond, Kenneth / Augustovski, Federico / Booth, Andrew / Bridges, John F.P. / Grimshaw, Jeremy et al. | 2019
13
Cost-of-Illness Studies in the United States: A Systematic Review of Methodologies Used for Direct Cost
Clabaugh, G. / Ward, M. M. | 2008
13
Cost-Benefit Analysis of Preventing Sudden Cardiac Deaths with an Implantable Cardioverter Defibrillator versus Amiodarone:
Caro, J. J. / Ward, A. / Deniz, H. B. / O'Brien, J. A. / Ehreth, J. L. | 2007
13
Utilization of ACE Inhibitors in Congestive Heart Failure among the Elderly in Quebec
| 1999
13
Modeling the Efficiency of Reaching a Target Intermediate End Point: A Case Study in Type 2 Diabetes in the United States
Caro, J. J. / Salas, M. / O'Brien, J. A. / Ishak, K. / Sung, J. / Raggio, G. | 2004
14
Cost-Effectiveness Analysis: Stress Ulcer Bleeding Prophylaxis with Proton Pump Inhibitors, H2 Receptor Antagonists
Barkun, A. N. / Adam, V. / Martel, M. / Marc, B. | 2013
14
Regulatory Issues for Health-Related Quality of Life-PhRMA Health Outcomes Committee Workshop, 1999
Santanello, N. C. / Baker, D. / Cappelleri, J. C. / Copley-Merriman, K. / DeMarinis, R. / Gagnon, J. P. / Hsuan, A. / Jackson, J. / Mahmoud, R. / Miller, D. | 2002
14
Thirty Years of Media Coverage on High Drug Prices in the United States—A Never-Ending Story or a Time for Change?
Leopold, C. / Chambers, J. D. / Wagner, A. K. | 2016
14
Economic Assessment of a Prophylactic Treatment of Recurrence of Ischemic Accidents by Lysine Acetylsalicylate
| 1999
14
Outcome of Acute Myocardial Infarction Patients with Maximal Individual Therapy (Mitra-Study)
| 1999
14
Road Traffic Accidents Are Associated with Benzodiazepine Use
| 1999
14
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report-Part III
Mansley, E. C. / Carroll, N. V. / Chen, K. S. / Shah, N. D. / Piech, C. T. / Hay, J. W. / Smeeding, J. | 2010
15
Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis
Cummins, E. / Asseburg, C. / Punekar, Y. S. / Shore, E. / Morris, J. / Briggs, A. / Fenwick, E. | 2011
15
New Benzodiazepine Use Is Associated with an Age-Related Risk of Hospitalization with Fracture and Other Trauma: A Population-Based Study
| 1999
15
Assessing the Saskatchewan Database for Outcomes Studies of Depression and Its Treatment
| 1999
15
The Effect of Supplemental Medical and Prescription Drug Coverage on Health Care Spending for Medicare Beneficiaries with Cancer
Erten, M. Z. / Davidoff, A. J. / Zuckerman, I. H. / Shaffer, T. / Dougherty, J. S. / Ke, X. / Stuart, B. | 2014
16
Economic Impact of Agitated and Aggressive Behaviors of Elderly Individuals Dwelling in the Community in France: 2. Cost Analysis
| 1999
16
Cost-Utility Analysis of Risperidone in Chronic Schizophrenia
| 1999
16
A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): A Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs
Doyle, J. J. / Casciano, J. / Arikian, S. / Tarride, J.-E. / Gonzalez, M. A. / Casciano, R. | 2001
16
Prevention and Management of Hyperphosphatemia with Sevelamer in Canada: Health and Economic Consequences
Huybrechts, K. F. / Caro, J. J. / O'Brien, J. A. | 2009
16
Economic Impact of Agitated and Aggressive Behaviors of Elderly Individuals Dwelling in the Community in France: 1. Epidemiology
| 1999
17
New French Coverage with Evidence Development for Innovative Medical Devices: Improvements and Unresolved Issues
Martelli, N. / van den Brink, H. l. / Borget, I. | 2016
17
Self-Monitoring of Blood Glucose in Diabetes: Is It Worth It?
| 1999
17
High-Dose Hemodialysis versus Conventional In-Center Hemodialysis: A Cost-Utility Analysis from a UK Payer Perspective
Liu, F. X. / Treharne, C. / Arici, M. / Crowe, L. / Culleton, B. | 2015
17
Patient-Held Instruments for Recording Ambulatory Care Resource Use: Experience in Patients with Diabetic Foot Ulcers
| 1999
18
Antithyroid Drugs or Radioiodine as First-Line Therapy of Graves' Hyperthyroidism in a Country with Strict Regulations for Radiation Protection?
| 1999
18
Cost-Effectiveness and Value of Information Analysis of Brief Interventions to Promote Physical Activity in Primary Care
GC, Vijay Singh / Suhrcke, Marc / Hardeman, Wendy / Sutton, Stephen / Wilson, Edward C.F. | 2018
18
Assessing the Value of Epoetin-� versus Autologous Blood Donation in Orthopedic Surgery: A Feasibility Study of Contingent Valuation
| 1999
18
How Well Have Practices Followed Guidelines in Prescribing Antihypertensive Drugs: The Role of Health Insurance
Guo, J. D. / Liu, G. G. / Christensen, D. B. / Fu, A. Z. | 2003
18
Measuring the Impact of Diabetic Foot Ulcers on Quality of Life from the Patient's Perspective
| 1999
18
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IV
Mullins, C. D. / Seal, B. / Seoane-Vazquez, E. / Sankaranarayanan, J. / Asche, C. V. / Jayadevappa, R. / Lee, W. C. / Romanus, D. K. / Wang, J. / Hay, J. W. | 2010
19
Epoetin-� Reduces Postoperative Length of Stay in Patients Undergoing Knee Replacement
| 1999
20
The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer
Carlson, J. J. / Garrison, L. P. / Ramsey, S. D. / Veenstra, D. L. | 2009
20
The Cost-Effectiveness of Itraconazole Solution in the Treatment of Oral Candidiasis in HIV/AIDS Patients: An International Comparison
| 1999
20
Pharmacoeconomic Efficiency of the Use of Protease Inhibitors for Hospital Inpatients with AIDS
| 1999
20
The Cost of Increasing Physical Activity and Maintaining Weight for Midlife Sedentary African American Women
Johnson, T. J. / E. Schoeny, M. / Fogg, L. / Wilbur, J. | 2016
21
Economic Consequences of Monoclonal Antibody 17-1A Adjuvant Therapy of Resected Dukes' C Colorectal Carcinoma in Germany
| 1999
21
The EQ-5D and the EuroQol Group
Lloyd, Andrew / Pickard, A. Simon | 2019
21
Quality of Life in Hodgkin's Disease: Results from the EORTC and GHSG Trials
| 1999
21
Outcome of Monoclonal Antibody 17-1A Adjuvant Therapy of Resected Colon Cancer Dukes' C in Germany: A Subgroup Analysis
| 1999
22
Estimating the Long-Term Cost-Effectiveness of Exenatide in the United States: An Adjunctive Treatment for Type 2 Diabetes Mellitus
Minshall, M. E. / Oglesby, A. K. / Wintle, M. E. / Valentine, W. J. / Roze, S. / Palmer, A. J. | 2008
22
Cost-Effectiveness of Gemcitabine as First-Line Therapy for Patients with Advanced Pancreatic Cancer
| 1999
22
Cost Estimation of Severe Neutropenia in Belgium
| 1999
22
The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS)
Manca, A. / Asseburg, C. / Bravo Vergel, Y. / Seymour, M. T. / Meade, A. / Stephens, R. / Parmar, M. / Sculpher, M. J. | 2012
22
Cost-Minimization in the Use of Colony-Stimulating Factors (CSFs) Based on Clinical Prediction Models (CPMs)
| 1999
22
The Cost-Effectiveness of a Pharmacogenetic Test: A Trial-Based Evaluation of TPMT Genotyping for Azathioprine
Thompson, A. J. / Newman, W. G. / Elliott, R. A. / Roberts, S. A. / Tricker, K. / Payne, K. | 2014
22
The Impact of Olanzapine, Risperidone, or Haloperidol on the Cost of Schizophrenia Care in a Medicaid Population
Gibson, P. J. / Damler, R. / Jackson, E. A. / Wilder, T. / Ramsey, J. L. | 2004
23
Quality of Life (QoL) of Patients with Low-Grade Non-Hodgkin's Lymphoma (Ig-NHL) Treated with Fludarabine (F) or Cyclophosphamide-Vincristine-Prednisone (CVP)
| 1999
23
Estimates of the Lifetime Direct Costs of Treatment for Metastatic Breast Cancer
Berkowitz, N. / Gupta, S. / Silberman, G. | 2000
23
Cost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy:
Moore, S. / Tumeh, J. / Wojtanowski, S. / Flowers, C. | 2007
23
Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol
Stolk, Elly / Ludwig, Kristina / Rand, Kim / van Hout, Ben / Ramos-Goñi, Juan Manuel | 2019
23
Cost-Effectiveness of Interventions for Reducing Road Traffic Injuries Related to Driving under the Influence of Alcohol
Ditsuwan, V. / Lennert Veerman, J. / Bertram, M. / Vos, T. | 2013
23
The Relationship between Profile-Based Quality of Life Scores and EuroQol-5D Scores in Breast Cancer Surgery Patients
| 1999
24
An Evaluation of Managing and Educating Patients on the Risk of Glucocorticoid-Induced Osteoporosis
McDonough, R. P. / Doucette, W. R. / Kumbera, P. / Klepser, D. G. | 2005
24
The New Injury Severity Score: Better Prediction of Functional Recovery after Musculoskeletal Injury
Sutherland, A. G. / Johnston, A. T. / Hutchison, J. D. | 2006
24
Efficacy of Cardiac Rehabilitation Therapy: A Prospective Multicenter Cohort Study
| 1999
24
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non–ST-segment elevation acute coronary syndromes
Schwenkglenks, M. / Brazier, J. E. / Szucs, T. D. / Fox, K. A. | 2011
24
Cost-Effectiveness of Lipid Modulator Agents
| 1999
24
Adapting Economic Analyses from One Country to Another: Do the WOSCOPS UK Findings Hold in Belgium?
| 1999
25
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report-Part V
Mycka, J. M. / Dellamano, R. / Kolassa, E. M. / Wonder, M. / Ghosh, S. / Hay, J. W. / Smeeding, J. | 2010
25
Potential Cost Savings of the 4 French Infiniti Catheter in Diagnostic Coronary Angiography
| 1999
25
Measuring Disease-Specific Symptom Impact: Development of the Atrial Fibrillation Impact Scale (AFIS)
| 1999
25
Using Classical Test Theory, Item Response Theory, and Rasch Measurement Theory to Evaluate Patient-Reported Outcome Measures: A Comparison of Worked Examples
Petrillo, J. / Cano, S. J. / McLeod, L. D. / Coon, C. D. | 2015
25
The Economic Impact of Hypertension Study from the Pistoia Project
| 1999
26
Impact of Clinical Sensitivity Analysis in an Evaluation of Primary Prevention of Coronary Heart Disease in Germany
| 1999
26
The Direct Cost and Incidence of Systemic Fungal Infections
Wilson, L. S. / Reyes, C. M. / Stolpman, M. / Speckman, J. / Allen, K. / Beney, J. | 2002
26
Cross-Cultural Adaptation of the Seattle Angina Questionnaire (SAQ) in 11 Countries
| 1999
27
Comparison of the Epidemiology and Costs Associated with Primary Prevention of Coronary Heart Disease in Five European Countries
| 1999
27
An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds
Nussbaum, Samuel R. / Carter, Marissa J. / Fife, Caroline E. / DaVanzo, Joan / Haught, Randall / Nusgart, Marcia / Cartwright, Donna | 2018
27
A Health Economic Evaluation of Hormone Replacement Therapy in Belgium
| 1999
27
Willingness to Pay of Patients with Painful-Irritable Bladder Syndrome
| 1999
28
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI
Shi, L. / Hodges, M. / Drummond, M. / Ahn, J. / Li, S. C. / Hu, S. / Augustovski, F. / Hay, J. W. / Smeeding, J. | 2010
28
Evaluating Clinical Outcomes of GERD Treatment Options Using Decision Analysis
| 1999
28
The Effects of Ulcer-Healing Drug Coprescription on NSAID-Induced Gastrointestinal Events: A Record Linkage Cohort Study
| 1999
28
Budgetary Impact of Varenicline in Smoking Cessation in the United Kingdom
Taylor, D. C. / Chu, P. / Rosen, V. M. / Baker, C. L. / Thompson, D. | 2009
28
Cost-Effectiveness of Integrating a Clinical Decision Rule and Staged Imaging Protocol for Diagnosis of Appendicitis
Gregory, S. / Kuntz, K. / Sainfort, F. o. / Kharbanda, A. | 2016
28
Pramipexole versus Levodopa in Patients with Early Parkinson's Disease: Effect on Generic and Disease-Specific Quality of Life
Noyes, K. / Dick, A. W. / Holloway, R. G. | 2006
29
Rate of Gastroprotective Agent Use, Diagnostic Tests, and Hospitalizations among Elderly Patients Who Started Arthrotec, a Fixed Combination of Misoprostol and Diclofenac
| 1999
29
Cross-Cultural Adaptation of the Patient Assessment of Constipation-Symptom Questionnaire (PAC-SYM)
| 1999
29
Computerized Health Information and the Demand for Medical Care
Wagner, T. H. / Jimison, H. B. | 2003
30
Cost-Minimization Analysis of Cefamandole and Tobramycin versus Standard Therapy in the Treatment of Patients with Local Appendicular Peritonitis
| 1999
30
Cost-Effectiveness of Levofloxacin versus Clarithromycin in Patients Evaluable for Clinical Efficacy in the Treatment of Acute Bacterial Sinusitis
| 1999
30
Compliance with American Diabetic Association (ADA) Recommendations in a Type 2 Diabetic Population in an Academic Family Medicine Center
| 1999
31
Clinical and Economic Characterization of Family Medicine Patients Receiving Antidepressant Drugs
| 1999
31
Economic Evaluation of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in Canada
Nuitjen, M. / McCormick, J. / Waibel, F. / Parison, D. | 2000
31
EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set
Kreimeier, Simone / Greiner, Wolfgang | 2019
31
Annual Direct Costs of Psychotropic Medications for the Treatment of Psychiatric Disorders in India
| 1999
31
Cost and Predictors of Lost Productive Time in Chronic Migraine and Episodic Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study
Serrano, D. / Manack, A. N. / Reed, M. L. / Buse, D. C. / Varon, S. F. / Lipton, R. B. | 2013
32
Modeling Choice Behavior for New Pharmaceutical Products
Bingham, M. F. / Johnson, F. R. / Miller, D. | 2001
32
Probabilistic Markov Model to Assess the Cost-Effectiveness of Bronchodilator Therapy in COPD Patients in Different Countries
Oostenbrink, J. B. / Rutten-van Molken, M. P. / Monz, B. U. / FitzGerald, J. M. | 2005
32
The Budget Impact Pharmacotherapy Selection for Major Depressive Disorder: A Multinational Study
| 1999
32
The Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease:
Brennan, A. / Akehurst, R. / Davis, S. / Sakai, H. / Abbott, V. | 2007
32
Evidence-Based Prediction of Statin Use with Lipid-Panel Data from the National Health and Nutrition Examination Survey
Gorevski, E. / Bian, B. / Kelton, C. M. / Martin Boone, J. E. / Guo, J. J. | 2012
32
Cost-Effectiveness of Fluvoxamine in the Treatment of Recurrent Depression in France
| 1999
33
Cost of Alzheimer's Disease Care in the United Kingdom
| 1999
33
Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States
Brown, Joshua D. / Sheer, Rich / Pasquale, Margaret / Sudharshan, Lavanya / Axelsen, Kirsten / Subedi, Prasun / Wiederkehr, Daniel / Brownfield, Fred / Kamal-Bahl, Sachin | 2018
33
Cross-Cultural Adaptation of the International Index of Erectile Function (IIEF) in 31 Countries
| 1999
33
Development of a New Disease-Specific Quality of Life Scale for Use in Schizophrenia
| 1999
34
Effect of Risperidone on the Cost of Nursing Home Care for Residents with Behavioral and Psychological Signs and Symptoms
| 1999
34
Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study
Leendertse, A. J. / Van Den Bemt, P. M. / Poolman, J. B. / Stoker, L. J. / Egberts, A. C. / Postma, M. J. | 2011
34
The Impact of Atypical Antipsychotic Medications on the Use of Health Care by Patients with Schizophrenia
Chen, L. / McCombs, J. S. / Park, J. | 2008
34
Results of Disease Management in Headache Treatment
| 1999
34
A UK Primary Care Database (UKPCD)-UK MediPlus as a Readily Available Research Tool for Determining the Incidence and Prevalence of Multiple Sclerosis, Its Treatment, Prescription Costs, and Referrals in UK Practice
| 1999
34
The Impact of Proton Pump Inhibitor Compliance on Health-Care Resource Utilization and Costs in Patients with Gastroesophageal Reflux Disease
Gosselin, A. / Luo, R. / Lohoues, H. / Toy, E. / Lewis, B. / Crawley, J. / Duh, M. S. | 2009
34
The Multinational Nature of Cost-Effectiveness Analyses Alongside Multinational Clinical Trials
Rivero-Arias, O. / Gray, A. | 2010
34
Cost-Utility Analysis of Platinum-Based Chemotherapy versus Taxane and Other Regimens for Ovarian Cancer
Lairson, D. R. / Parikh, R. C. / Cormier, J. N. / Du, X. L. | 2014
35
The Incidence and Cost of Hospitalization for 5-FU Toxicity among Medicare Beneficiaries with Metastatic Colorectal Cancer
Delea, T. E. / Vera-Llonch, M. / Edelsberg, J. S. / McGarry, L. / Anton, S. / Ulcickas-Yood, M. / Oster, G. | 2002
35
A Foundation Study for Cost-Effectiveness Analysis: The Definition of Economic Parameters and Clinical Endpoints in Parkinson's Disease
| 1999
35
Quality of Life and Functional Status Measures in Advanced Parkinson's Patients Treated with Pramipexole, Bromocriptine, or Placebo
| 1999
35
Comparing Measurement Properties of the EQ-5D-3L, ICECAP-O, and ASCOT in Frail Older Adults
van Leeuwen, K. M. / Bosmans, J. E. / Jansen, A. P. / Hoogendijk, E. O. / van Tulder, M. W. / van der Horst, H. E. / Ostelo, R. W. | 2015
36
A Pharmacoeconomic Evaluation of Seven-Valent Pneumococcal Conjugate Vaccine in Spain
Asensi, F. / De Jose, M. / Lorente, M. / Moraga, F. / Ciuryla, V. / Arikian, S. / Casciano, R. / Vento, M. | 2004
36
Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study
Hayes, A. / Arima, H. / Woodward, M. / Chalmers, J. / Poulter, N. / Hamet, P. / Clarke, P. | 2016
36
Cross-Cultural Adaptation of the Functional Assessment of Multiple Sclerosis (FAMS) Questionnaire in Nine Countries
| 1999
36
Impact of a Cost-Sharing Drug Insurance Plan on Drug Utilization among Individuals Receiving Social Assistance
| 1999
37
The Effect of Age on Cost-Effectiveness in the Treatment of Moderate Asthma
| 1999
37
Cost-Effectiveness of Pramipexole in Parkinson's Disease in Three Countries
| 1999
37
Characteristics of Chronic Airway Disease Patients Started on Nebulized Ipratropium Solution
| 1999
38
Cost-Effectiveness Analysis of a Fixed Combination (Diclofenac + Misoprostol) in the Prevention of Gastropathy in Arthritis Patients in Belgium
| 1999
38
Incremental Cost of Disease in Nosocomial Pneumonia from a Hospital's Perspective: A Feasibility Study
| 1999
38
Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice
Yang, Zhihao / Luo, Nan / Bonsel, Gouke / Busschbach, Jan / Stolk, Elly | 2019
38
Economic Impact of Smoking in Germany
| 1999
39
Discrepancies between Patient-Reported Outcomes and Clinician-Reported Outcomes in Chronic Venous Disease, Irritable Bowel Syndrome, and Peripheral Arterial Occlusive Disease
Chassany, O. / Le-Jeunne, P. / Duracinsky, M. / Schwalm, M. S. / Mathieu, M. | 2006
39
Quality of Life Scores as Predictors of Future Healthcare Resource Use in Patients with Arthritis
| 1999
39
Modeling Cost-Effectiveness of Cervical Cancer Screening in Hungary
Vok&#x00F3 / Z. x. / Nagyj&#x00E1 / nosi, L. x. / Margitai, B. x. / K&#x00F6 / vi, R. / T&#x00F3 / th, Z. x. / L&#x00E1 et al. | 2012
39
Cost of Illness in Early Rheumatoid Arthritis Stratified for Social Status
| 1999
39
Economic Appraisal of a Community-Wide Cardiovascular Health Awareness Program
Goeree, R. / von Keyserlingk, C. / Burke, N. / He, J. / Kaczorowski, J. / Chambers, L. / Dolovich, L. / Michael Paterson, J. / Zagorski, B. | 2013
40
Medication Compliance and Expenditure Impact Associated with Pharmacist's Cognitive Service Interventions
| 1999
40
Economic Assessment of a Maintenance Treatment Strategy in Prevention of Recurrent Depressive Disorder
Dardennes, R. M. / LaFuma, A. / Fagnani, F. / Pribil, C. / Bisserbe, J. C. / Berdeaux, G. | 2000
40
Survival Gains and Degree of Therapeutic Innovation
| 1999
40
Functional Status and Somatization as Predictors of Medical Offset in Anxious and Depressed Patients
Fifer, S. K. / Buesching, D. P. / Henke, C. J. / Potter, L. P. / Mathias, S. D. / Schonfeld, W. H. / Patrick, D. L. | 2003
40
Running Cost of Treating a Patient in a General Medical Ward in Sultan Qaboos University Hospital in Oman
| 1999
40
Potential for Cost-Savings in the Care of Hospitalized Low-Risk Community-Acquired Pneumonia Patients in China
Zhou, Q. t. / He, B. / Zhu, H. | 2009
41
Linking HRQOLS to Large National Data Sets: EuroQol and HUI Indices
| 1999
41
Standards for Instrument Migration When Implementing Paper Patient-Reported Outcome Instruments Electronically: Recommendations from a Qualitative Synthesis of Cognitive Interview and Usability Studies
Muehlhausen, Willie / Byrom, Bill / Skerritt, Barbara / McCarthy, Marie / McDowell, Bryan / Sohn, Jeremy | 2018
41
Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003
Cipriano, L. E. / Romanus, D. / Earle, C. C. / Neville, B. A. / Halpern, E. F. / Gazelle, G. S. / McMahon, P. M. | 2011
41
Using a Surrogate Sample to Derive Patient Preferences for a Cost-Utility Analyses in a Randomized Clinical Trial
| 1999
42
Concept Elicitation Within Patient-Powered Research Networks: A Feasibility Study in Chronic Lymphocytic Leukemia
McCarrier, K. P. / Bull, S. / Fleming, S. / Simacek, K. / Wicks, P. / Cella, D. / Pierson, R. | 2016
42
Cost-Effectiveness Analysis of a Quality-Controlled Mammography Screening Program from the Swiss Statutory Health-Care Perspective: Quantitative Assessment of the Most Influential Factors:
Neeser, K. / Szucs, T. / Bulliard, J. L. / Bachmann, G. / Schramm, W. | 2007
42
Cost-Benefit Analysis of Preventing Nosocomial Bloodstream Infections among Hemodialysis Patients in Canada in 2004
Hong, Z. / Wu, J. / Tisdell, C. / O'Leary, C. / Gomes, J. / Wen, S. W. / Njoo, H. | 2010
42
Meta-Analysis of Economic Evaluations: A Methodological Approach and Case Study
| 1999
42
Advanced Sensitivity Analysis by the Integration of Point-Sensitivity and Range-Sensitivity Using Probability Distributions
| 1999
42
Diminishing the Cost of Highly Prescribed Drugs in the Comunidad Valenciana (Spain)
| 1999
43
Impact of Osteoporosis on High-Cost Chronic Diseases
Thayer, S. W. / Stolshek, B. S. / Gomez Rey, G. / Seare, J. G. | 2014
44
Monte Carlo Simulation in Healthcare Models
| 1999
44
Cost Effectiveness Analysis of Interferon Beta in Multiple Sclerosis: A Markov Process Analysis
Nuijten, M. J. C. / Hutton, J. | 2002
44
Measuring Health-Related Quality of Life by Experiences: The Experience Sampling Method
Maes, I. H. / Delespaul, P. A. / Peters, M. L. / White, M. P. / van Horn, Y. / Schruers, K. / Anteunis, L. / Joore, M. | 2015
44
Medication Compliance and Persistence: Terminology and Definitions
Cramer, J. A. / Roy, A. / Burrell, A. / Fairchild, C. J. / Fuldeore, M. J. / Ollendorf, D. A. / Wong, P. K. | 2008
44
A Natural History of Alzheimer's Disease: Path-Dependent Evaluation of Clinical and Economic Outcomes Using Decision Database Methodology
| 1999
45
Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang, Fan / Devlin, Nancy / Luo, Nan | 2019
45
Decision Analysis in Cancer Therapy, A New Way for Evaluation Outcomes with the Analytic Hierarchy Process (AHP)
| 1999
45
The Appropriateness of Common Medical Data Sources: Randomized Trials, Meta-Analyses, Epidemiological and Observational Studies for Pharmacoeconomic Analyses
| 1999
45
The Development and Implementation of Formulary Submission Guidelines for Managed Care in the United States
| 1999
45
Developing Interactive Computer Software for Evaluating the Economic and Clinical Outcomes of Various Treatment Strategies
| 1999
46
The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis
Thompson, M. / Pasquale, M. / Grima, D. / Moehrke, W. / Kruse, H. P. | 2010
46
Development of a Composite Questionnaire, the Valuation of Lost Productivity, to Value Productivity Losses: Application in Rheumatoid Arthritis
Zhang, W. / Bansback, N. / Boonen, A. / Severens, J. L. / Anis, A. H. | 2012
46
Pro and Con: Use of Data from Foreign Pharmacoeconomic Investigations in Russia
| 1999
46
Standardization in the Public Health System of Russia: The First Experience
| 1999
46
Cost-Effectiveness of Gene-Expression Profiling for Tumor-Site Origin
Hornberger, J. / Degtiar, I. / Gutierrez, H. / Shewade, A. / David Henner, W. / Becker, S. / Varadachary, G. / Raab, S. | 2013
47
The DARTS Diabetes Database: How Can Quality of Life Measurements for Outcomes Research Be Incorporated?
| 1999
47
The Effects of Laparoscopic Surgery and Nosocomial Infections on the Cost of Care: Evidence from Three Common Surgical Procedures
Gunnarsson, C. / Rizzo, J. A. / Hochheiser, L. | 2009
47
Effect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy
Cosler, L. E. / Sivasubramaniam, V. / Agboola, O. / Crawford, J. / Dale, D. / Lyman, G. H. | 2005
47
EM2: The Impact of Hospital Costing Methods on Statistical Power in Multinational Clinical Trials
Reed, S. D. / Friedman, J. Y. / Malenbaum, J. H. / Gnanasakthy, A. / Schulman, K. A. | 2001
47
EM1: Risk Attitude: Association With Magnitude Of Risk and Patient Characteristics
Singer, M. E. / Beaird, H. / Miller, L. A. N. | 2001
47
Measurement of HRQL Using EQ-5D in Patients with Type 2 Diabetes Mellitus in Japan
Sakamaki, H. / Ikeda, S. / Ikegami, N. / Uchigata, Y. / Iwamoto, Y. / Origasa, H. / Otani, T. / Otani, Y. | 2006
47
The Use of Proxies to Collect Healthcare Resources and Quality of Life Data
| 1999
47
Standard Procedures for Economic Evaluation: Using a Computer Program for Reporting Economic Evaluations Results (REER)
| 1999
48
EM4: Can Unit Costs Be Compared Across Western European Countries?
Brown, R. / Hutton, J. / Nuijten, M. | 2001
48
Health Status and Quality of Life Measures in International Clinical Research
| 1999
48
Estimating Population Budget and Health Impacts of New Treatments
| 1999
48
Classifying Patients by Antipsychotic Adherence Patterns Using Latent Class Analysis: Characteristics of Nonadherent Groups in the California Medicaid (Medi-Cal) Program
Ahn, J. / McCombs, J. S. / Jung, C. / Croudace, T. J. / McDonnell, D. / Ascher-Svanum, H. / Edgell, E. T. / Shi, L. | 2008
48
Estimating Drug Effects: From Clinical Trial Results to Actual Practice
| 1999
48
MD1: Cost-Effectiveness of Airline Defibrillators: Is Peace of Mind More Important Than Saving Lives?
Cram, P. / Vijan, S. / Wolbrink, A. M. / Fendrick, A. M. | 2001
48
EM3: Response Bias Among Likely Clinical Trial Participants
McDonnell, D. D. / Donohue, J. A. | 2001
49
Handling Survival Data in Cost-Effectiveness Analysis
| 1999
49
D1: Development and Validation of a Screening Instrument for Gastroesophageal Reflux Disease
Fullerton, S. / Emery, K. / Reyes, E. / Lee, J. / Shaw, M. / Shafiroff, J. / Willian, M. K. / Grogg, A. / Sadik, K. / Ofman, J. | 2000
49
D3: A Pharmacoeconomic Model to Assess the Cost-Effectiveness of Trovafloxacin Compared to Ceftazidime for Nosocomial Pneumonia in a Public Hospital Setting in Hong Kong
Lee, K. K. C. / You, J. H. S. / Ho, S. S. S. / Chan, T. Y. K. | 2000
49
Economic Evaluation of Rehabilitation Programs: The Perspective of Social Old Age Insurance Funds in Germany
| 1999
49
EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom
Hernandez Alava, Monica / Wailoo, Allan / Grimm, Sabine / Pudney, Stephen / Gomes, Manuel / Sadique, Zia / Meads, David / O’Dwyer, John / Barton, Garry / Irvine, Lisa | 2018
49
MD3: The Diagnostic Accuracy of 18FDG-PET In Patients With Recurrent Papillary or Follicular Thyroid Cancer: A Systematic Review
Hooft, L. / Hoekstra, O. S. | 2001
49
Designing an International Piggyback Study: Providing the Foundation
| 1999
49
D2: Cost Utility of Docetaxel vs Vinorelbine or Paclitaxel in Advanced Breast Cancer
Brown, R. / Hutton, J. | 2000
49
MD2: Analysis of The Impact of Assistive Living Devices on Self-Assessed Health Status Rating
Rodney, A. B. / Xiao, H. / Robertson, T. | 2001
49
MD4: Inclusion of Indirect Cost in Economic Outcomes Analyses of Medical Devices: How Important Is It?
Subramanian, S. / Justason, B. J. | 2001
50
QL2: Logical Consistency and the Valuation of Health: An Analysis Of US Survey Data
Craig, B. M. / Kind, P. | 2001
50
D4: Economic Analysis of Warfarin in Outpatients with Atrial Fibrillation: Innovator Versus Generic
Mittman, N. / Bartle, W. / Walker, S. E. / Oh, P. I. | 2000
50
The Bootstrap Statistical Method for the Pharmacoeconomic Cost Analysis of Skewed Data
| 1999
50
Selecting Bolt-On Dimensions for the EQ-5D: Examining Their Contribution to Health-Related Quality of Life
Finch, Aureliano Paolo / Brazier, John Edward / Mukuria, Clara | 2019
50
R1: Quantifying the Impact of Interactions Between HMG-COA Reductase Inhibitors (Stains) and Cytochrome P-450 Interacting Drugs on Healthcare Utilization: A Population-Based Study
Iskedjian, M. / Metege, C. J. / Einarson, T. R. / Yogendran, M. / Mukherjee, J. | 2000
50
Self-Reported Resource Utilization Data in Pharmacoeconomic Trials: Their Use and Impact on Study Validity
| 1999
50
QL1: Does Socioeconomic Status Affect The Valuation Of Health?
Asada, Y. / Stout, N. K. / Kind, P. | 2001
51
R2: Risk Factors for Short-Term Diabetes Complications: An Analysis of Linked Administrative Claims and Clinical Laboratory Data
Menzin, J. / Boulanger, L. / Friedman, M. / Langley-Hawthorne, C. / Cavanaugh, R. | 2000
51
R3: Donepezil Use and Impact on Cost Among Patients with Alzheimer's Disease
West, W. A. / Prashker, M. / Merriman, L. / Anderson, J. / Miller, D. | 2000
51
Differences in Health Services Utilization and Costs between Antihypertensive Medication Users Versus Nonusers in Adults with Diabetes and Concomitant Hypertension from Medical Expenditure Panel Survey Pooled Years 2006 to 2009
Davis-Ajami, M. L. / Wu, J. / Fink, J. C. | 2014
51
R4: Availability of Highly Active Antiretroviral Therapy Associated with Increased Survival and Lower Costs at a VA Medical Center
McCollum, M. / Malone, D. C. / MacWhinney, S. / Bessesen, M. | 2000
51
HP1: Ethnic Disparity of Combination Ribavirin/Interferon Alfa-2b Prescribing Among Hepatitis C-Infected Members in a Managed Care Organization (MCO)
Phillips, A. L. / Schaffer, M. / Mansukani, S. | 2001
51
Drug-Related Problems and Quality of Life in Arthritis and Low Back Pain Sufferers
Ernst, M. E. / Iyer, S. S. / Doucette, W. R. | 2003
51
QL3: Quality Of Life in Product Labeling: A Review of Marketed Drug Products
Chopra, T. / Shah, S. N. / McLaughlin-Miley, C. / Hinton, J. | 2001
51
QL4: Quality Of Life Messages in Prescription Drug Advertisements in Leading Medical Journals, 1990-99
Zivin, K. / Neumann, P. | 2001
52
DH2: Medicare's Extended Immunosuppression Coverage Improved Middle-Income Renal Graft Survival
Woodward, R. S. / Schnitzler, M. A. / Hollenbeak, C. S. / Lowell, J. A. / Singer, G. G. / Cohen, D. S. / Spitznagel, E. L. / Brennan, D. C. | 2000
52
DH1: An Analysis of the Impact of Medication Non-Adherence and Type of Medication on Outcome Domains Using the SCAP Health Questionnaire
Russo, P. / Dirani, R. | 2000
52
An Exploratory Study to Test the Impact on Three “Bolt-On” Items to the EQ-5D
Yang, Y. / Rowen, D. / Brazier, J. / Tsuchiya, A. / Young, T. / Longworth, L. | 2015
52
HP3: Incorporating Clinical Outcomes and Economic Consequences into Drug Formulary Decisions: Evaluation of 30 Months of Experience
Atherly, D. E. / Sullivan, S. D. / Fullerton, D. S. / Sturm, L. L. | 2001
52
HP2: The Role Of Outlier Payments in Medicare Patients with Severe Sepsis
Cooper, L. M. / Linde-Zwirble, W. T. | 2001
52
DH3: Public Report Spurs Hospital Mortality Reduction
Czerwinski, A. A. / Horgan, M. M. | 2000
52
Using Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: A Cost-Utility Analysis in Spain
Latour-Perez, J. / Navarro-Ruiz, A. / Ridao-Lopez, M. / Cervera-Montes, M. | 2004
53
Q1: Consumer and Staff Validation of a Self-Administered Health-Related Quality of Life Instrument for Individuals with Schizophrenia
Barr, J. T. / Schumacher, G. E. / Mason, E. J. / Ohman, S. M. / Hanson, A. | 2000
53
DH4: Schizophrenic Care and Assessment Program (SCAP): Impact of Clinical and Functional Status and Type of Medication Treatment on Outpatient Psychiatric Utilization
Russo, P. / Dirani, R. / Smith, M. | 2000
53
The CHD challenge: Comparing four cost-effectiveness models
Turner, D. / Raftery, J. / Cooper, K. / Fairbank, E. / Palmer, S. / Ward, S. / Ara, R. | 2011
53
HP4: Assessing Lifestyle Drugs for Drug Benefit Formularies: A Cost-Utility Analysis Of Orlistat and Sibutramine for the Treatment of Obesity in Adults
Trakas, K. / Oh, P. / Leiter, L. / Shear, N. H. | 2001
53
An Empirical Study of Two Alternative Comparators for Use in Time Trade-Off Studies
Shah, K. / Mulhern, B. / Longworth, L. / Janssen, M. F. | 2016
53
CN1: Utilities of Metastatic Breast Cancer Patients (PT) Treated With Taxanes Compared to Utilities of Oncology Nurses (NUR)
Hauser, R. / Theriault, R. / Wilson, J. / Shepherd, M. / Lawson, K. / Koeller, J. | 2001
53
An Assessment of the Impact of Informative Dropout and Nonresponse in Measuring Health-Related Quality of Life Using the EuroQol (EQ-5D) Descriptive System
Ratcliffe, J. / Young, T. / Longworth, L. / Buxton, M. | 2005
53
CN2: Effect of Including (Versus Excluding) Fates Worse Than Death on Utility Measurement
Franic, D. M. / Pathak, D. S. | 2001
54
Q3: Health-Related Quality of Life (HRQOL) in African American Men with Prostate Cancer: Data from CaPSURE
Lubeck, D. P. / Grossfeld, G. / Ray, P. / Flanders, S. C. / Carroll, P. R. | 2000
54
Q2: Patient Preferences for Treatment Outcomes in Disabling Tremor
Leidy, N. K. / Palmer, C. / Coughlin, C. / Halpern, M. / Charles, D. | 2000
54
Q4: Minimum Meaningful Difference Scores for the Irritable Bowel Syndrome Quality of Life Questionnaire (IBSQOL)
Watson, M. E. | 2000
54
The Effect of Disease, Functional Status, and Relapses on the Utility of People with Multiple Sclerosis in the UK:
Orme, M. / Kerrigan, J. / Tyas, D. / Russell, N. / Nixon, R. | 2007
54
CN4: Economic Evaluation of Gemzar/Cisplatin Relative to Other Cisplatin Based Treatments for Non Small Cell Lung (NSCLC) Cancer In The UK
Botwood, N. / McKendrick, J. / Aristides, M. / Lees, M. / Maniadakis, N. / Wein, W. / Stephenson, D. | 2001
54
CN3: Cost-Effectiveness Analysis of Irinotecan+5FU/FA Alone as First-Line Therapy in Advanced Colorectal Cancer in the UK
Brown, R. / Sorensen, S. / Burrell, A. / Bearne, A. | 2001
54
Developing Better Economic Models of Osteoporosis: Considerations for the Calculation of the Relative Risk of Fracture
Black, D. M. / Palermo, L. / Grima, D. T. | 2006
55
ICP2: The Relative Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) and Tricyclic Antidepressants (TCAs) in Reducing Worker Absenteeism
Treglia, M. / Neslusan, C. | 2000
55
The Burden of Migraine in the United States: Current and Emerging Perspectives on Disease Management and Economic Analysis
Hazard, E. / Munakata, J. / Bigal, M. E. / Rupnow, M. F. / Lipton, R. B. | 2009
55
CV2: Indirect Comparisons of Drugs Using Meta-Analysis: Validation of Results
Ross, S. D. / Klawansky, S. / Allen, I. E. | 2001
55
CV3: Do Short-Acting Opiates in Off-Pump Bypass Surgery Reduce Length of Stay or Total Hospital Costs?
Reddy, P. / Feret, B. / Kulicki, L. / Jordan, S. / Donahue, S. / Quercia, R. | 2001
55
Updating and Confirming an Industry-Sponsored Pharmacoeconomic Model: Comparing Two Antipsychotics in the Treatment of Schizophrenia
Graham, C. N. / Mauskopf, J. A. / Lawson, A. H. / Ascher-Svanum, H. / Bruhn, D. | 2012
55
CV1: The Value of Compliance: Evidence From Two Patient Cohorts
McGuigan, K. A. / Sokol, M. / Yao, J. / Haynes, J. / Qian, Q. / Boscarino, J. / Epstein, R. | 2001
55
Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
Hoyle, M. / Green, C. / Thompson-Coon, J. / Liu, Z. / Welch, K. / Moxham, T. / Stein, K. | 2010
55
A Method for Identifying the Financial Burden of Hospitalized Infants on Families
Leader, S. / Jacobson, P. / Marcin, J. / Vardis, R. / Sorrentino, M. / Murray, D. | 2002
55
ICP1: Incorporating Measurement of Indirect Costs in the Evaluation of an Asthma Health Management Program
Ershoff, D. H. / Buchner, D. A. | 2000
56
CV5: The Cost-Effectiveness of Lifetime Factor VIII Prophylaxis in the Treatment of Severe Hemophilia A
Charles, R. A. / Hay, J. | 2001
56
ICP4: Health State Preferences in Diabetic Peripheral Neuropathy
Devine, E. B. / Sullivan, S. D. / Lew, D. P. / Veenstra, D. L. | 2000
56
CAN1: Comparison of Cost of Asthma Treatment Between Patients Treated with Anti-Inflammatories Versus Bronchodilators
Huse, D. M. / Russell, M. W. / Weiss, S. T. / Hartz, S. C. | 2000
56
CV4: Using UK Observational Data to Identify Possibilities for the Cost-Effective Improvement of the Treatment Of Atrial Fibrillation
Piercy, J. / James, P. / Baum, D. / Kuester, L. | 2001
56
ICP3: Factors Influencing Patient Willingness to Pay for Diabetes Disease State Management Programs
Barner, J. C. | 2000
57
Does Epoetin Alfa Improve Health-Related Quality of Life in Chronically Ill Patients with Anemia? Summary of Trials of Cancer, HIV/AIDS, and Chronic Kidney Disease
Kimel, M. / Leidy, N. K. / Mannix, S. / Dixon, J. | 2008
57
CAN3: Baseline Cost of Illness of Parkinson's Disease in a Large Healthcare Plan
Heaton, A. H. / Martin, S. L. / Littlefield, R. S. | 2000
57
EQ-5D: Moving from Three Levels to Five
Lloyd, Andrew | 2018
57
CV6: Economic Evaluation of Dalteparin, Enoxaparin and Unfractionated Heparin in the Treatment of Deep Vein Thrombosis
Risebrough, N. A. / Mittmann, N. | 2001
57
CAN2: Shorter Hospital Length of Stay for Coronary Angioplasty Patients Who Receive Abciximab Versus Eptifibatide or Tirofiban
Lage, M. J. / Barber, B. L. / Scherer, J. / McCollam, P. | 2000
57
The Optimality of Different Strategies for Supplemental Staging of Non–Small-Cell Lung Cancer: A Health Economic Decision Analysis
S&#x000F8 / gaard, R. / Fischer, B. M. / Mortensen, J. / Rasmussen, T. R. / Lassen, U. | 2013
57
CV7: Cost-Effectiveness of Cardiovascular Disease (CVD) Prevention by Reducing Postprandial Hyperglycemia
Glick, H. / Qiao, Q. / Grueger, J. | 2001
57
CV8: Work-Related Outcomes of Patients Six Months After Myocardial Infarction
Erickson, S. R. / McBurney, C. R. / Kline-Rogers, E. M. / Cooper, J. V. / Mani, O. C. M. / Eagle, K. A. | 2001
58
CEB2: Cost-Effectiveness of Meningococcal Vaccine in the UK
Brown, R. E. / Sorensen, S. / Batista, C. / Nuijten, M. | 2000
58
DG2: The Incremental Cost of Diabetes in Chronic Illness Co-Occurrences
Garis, R. I. / Farmer, K. C. / Arora, M. | 2001
58
CEB1: Pharmacogenomics: Evaluating the Economic Impact
Veenstra, D. L. / Higashi, M. K. | 2000
58
CAN4: Is Prior Community Antibiotic Treatment of Patients Hospitalised with Lower Respiratory Tract Infection Associated with Reduced In-Hospital Mortality and Length of Stay?
Steinke, D. / Donnan, P. / MacDonald, T. / Davey, P. | 2000
58
DG1: The Relationship of Diabetes Symptoms and Health-Related Quality Of Life
Pfalzgraf, A. R. / Nau, D. P. | 2001
59
Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments
Janssen, Ellen M. / Hauber, A. Brett / Bridges, John F.P. | 2018
59
DG4: Disease Severity Determines Cost of Gastroesophageal Reflux Disease in a Midwest USA Health Care Plan
Brelje, T. / Heaton, A. / Martin, S. / Bhattacharjya, A. / Dodd, S. / Thornhill, J. | 2001
59
DUC1: Drug Utilization of Cisapride and Contraindicated Drugs in a US Managed Care Population
Guo, J. J. / Jones, J. K. / Fife, D. / Curkendall, S. / Goehring, E. / She, D. | 2000
59
ID1: Development of a Stochastic Decision Analysis Model of Treatment of Pyelonephritis from the Results of an RCT
Davey, P. / Wang, J. / Claxton, K. / Fenwick, E. / Sculpher, M. / Talan, D. | 2001
59
CEB3: Cost-Effectiveness of Prevention of Coronary Heart Disease (CHD) with Simvastatin in Poland
Kuzniar, J. / Orlewska, E. / Hermanowski, T. / Romandzuk, W. / Splawinski, J. | 2000
59
CEB4: The Cost-Effectiveness of Fixed-Dose Combination of Diclofenac and Misoprostol in Prevention of NSAID-Induced Ulcers in Rheumatoid Arthritis Patients in Poland
Orlewska, E. | 2000
59
Development and Initial Validation of an Instrument to Measure Physician-Pharmacist Collaboration from the Physician Perspective
Zillich, A. J. / Doucette, W. R. / Carter, B. L. | 2005
59
Economic Burden of Long-Term Complications of Deep Vein Thrombosis after Total Hip Replacement Surgery in the United States
Caprini, J. A. / Botteman, M. F. / Stephens, J. M. / Nadipelli, V. / Ewing, M. M. / Brandt, S. / Pashos, C. L. / Cohen, A. T. | 2003
59
DG3: A Retrospective Evaluation of Nonsteroidal Anti-Inflammatory Drug-Induced Gastrointestinal Complications Among Adults in a Managed Care Health Plan
Dodd, M. A. / D Angio, R. / Gupchup, G. V. / Nelson, C. | 2001
59
A Comparison of Depressive Symptoms in Stroke and Primary Care: Applying Rasch Models to Evaluate the Center for Epidemiologic Studies-Depression Scale
Pickard, A. S. / Dalal, M. R. / Bushnell, D. M. | 2006
60
DUC3: Smoking Cessation Success Rates with Drug Therapy in a Sample of Medicaid Patients
Fincham, J. E. / Braman, K. S. / McNees, G. E. | 2000
60
DUC2: Insurance Claims Costs for Overactive Bladder in Adults
Zhou, Z. / Jensen, G. A. | 2000
60
ID3: Cost-Effectiveness Analysis of An Intranasal Influenza Vaccine for Healthy Children
Luce, B. / Zangwill, K. / Palmer, C. / Mendelman, P. / Yan, L. / Wolff, M. / Cho, I. / Iacuzio, D. / Belshe, B. | 2001
60
A Simple and Practical Index to Measure Dementia-Related Quality of Life
Arons, A. M. / Schölzel-Dorenbos, C. J. / Olde Rikkert, M. G. / Krabbe, P. F. | 2016
60
ID2: Health Values for the Lipodystrophy Syndrome
Lenert, L. A. / Fedderson, M. / Sturley, A. / Lee, D. | 2001
61
MH1: The Impact of Second-Generation Antipsychotic Medications on Ambulatory Patients With Schizophrenia
Mulani, P. M. / McCombs, J. | 2001
61
ID4: The Confusion Between Septicemia and Severe Sepsis
Linde-Zwirble, W. T. / Ball, D. E. / Cooper, L. M. / Lidicker, J. / Angus, D. C. | 2001
61
MH2: Future Employability: A New Approach to Cost-Effectiveness Analysis of Antipsychotic Therapy
Ganguly, R. / Miller, L. S. / Martin, B. C. | 2001
61
Economic Evaluation of Palliative Management versus Peritoneal Dialysis and Hemodialysis for End-Stage Renal Disease: Evidence for Coverage Decisions in Thailand:
Teerawattananon, Y. / Mugford, M. / Tangcharoensathien, V. | 2007
61
MI1: Identifying Factors Associated with High and Low Cost Asthmatics: Opportunities for Disease Management Using Automatic Interaction Detection
Boscarino, J. A. / Zhao, Z. / Andrews, K. W. / Sokol, M. C. / Yao, J. / McGuigan, K. A. / Gutierrez, B. / Refowitz, R. | 2000
61
MI2: The Number Needed to Treat Approach: Evaluating the Clinical Relevance of Fexofenadine in Seasonal Allergic Rhinitis
Crawford, B. / Marquis, P. / Offord, S. | 2000
61
The economic burden of Medicare-eligible patients by multiple sclerosis type
Gilden, D. M. / Kubisiak, J. / Zbrozek, A. S. | 2011
61
Relationships of Clinical, Psychologic, and Individual Factors with the Functional Status of Neck Pain Patients
Luo, X. / Edwards, C. L. / Richardson, W. / Hey, L. | 2004
61
DUC4: High Users of beta~2-Agonists: Are Medicaid Recipients Being Treated According to National Asthma Guidelines?
Reddy, P. / Kelly, E. / Kophazi, M. / Geary, E. / Markelon, J. / Welter, K. | 2000
61
Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma
Hoyle, M. / Green, C. / Thompson-Coon, J. / Liu, Z. / Welch, K. / Moxham, T. / Stein, K. | 2010
61
Estimating Quality-Adjusted Life-Year Loss Due to Noncommunicable Diseases in Korean Adults through to the Year 2040
Ock, M. / Han, J. W. / Lee, J. Y. / Kim, S. H. / Jo, M. W. | 2015
62
MI4: A Framework for Cost-Effectiveness Analysis from Clinical Trial Data
O'Hagan, A. / Stevens, J. W. | 2000
62
Development of a Symptom Index for Patients with Primary Brain Tumors
Lai, J. S. / Jensen, S. E. / Beaumont, J. L. / Abernethy, A. P. / Jacobsen, P. B. / Syrjala, K. / Raizer, J. J. / Cella, D. | 2014
62
MH4: Application of the Rasch Model to the SF36 Mental Health 5 Item Scale (MH5)
Perneger, T. V. / Bovier, P. A. | 2001
62
MH3: Clinical Assessment of Quality of Life Among Schizophrenia Patients With Deficit Syndrome
Russo, P. / Kirkpatrick, B. | 2001
62
Future Directions in Valuing Benefits for Estimating QALYs: Is Time Up for the EQ-5D?
Brazier, John Edward / Rowen, Donna / Lloyd, Andrew / Karimi, Milad | 2019
62
MI3: Reliability and Validity of International Prostate Symptome Score (I-PSS) for Early Assessment of Symptoms in the Treatment of Benign Prostate Hyperplasia (BPH)
Singh, A. / Ashraf, T. / Verlinden, M. H. | 2000
63
MS1: Cost-Effectiveness of Interventions For Lateral Epicondylitis: Results from a Randomized Controlled Trial in Primary Care
Korthals-de Bos, I. B. C. / Smidt, N. / Tulder, M. / Bouter, L. | 2001
63
MS2: Responsiveness to Change of the SF-36 in Rapolo, a Longitudinal Study of Rheumatoid Arthritis Patients Treated With Etanercept
Lubeck, D. P. / Yelin, E. / Katz, P. / Roepke, L. / Wanke, L. A. / Buatti, M. | 2001
63
S1: Impact of Community-Acquired Pneumonia Treatment Guidelines on Length of Stay and Cost
Merchant, S. V. / Mullins, C. D. / Cooke, C. E. | 2000
63
S3: Statistical Method for Modeling Dual Selection Bias: Woodwork Effect and Drug Selection Bias Among Multiple Alternatives
Shi, L. / McCombs, J. S. | 2000
63
MS3: Correlation of a Generic Health-Related Quality of Life Questionnaire and Self-Administered Rheumatoid Arthritis Disease Activity Instrument
Kim, S. S. / Drabinski, A. M. / Williams, G. R. / Formica, C. A. | 2001
63
S2: Use of Estrogen Replacement Therapy in Maryland Medicaid Females
Huang, X. / Weiss, S. R. / Zuckerman, I. H. / Hsu, V. D. | 2000
64
BT2: Direct Costs of Obesity in Portugal
Pereira, J. / Mateus, C. / Amaral, M. J. | 2000
64
BT1: Postoperative Pain Severity After Abdominal or Orthopedic Surgery: Interim Results
Strassels, S. / Chen, C. / Carr, D. / McDonagh, M. / Gouveia, W. / Wurm, H. | 2000
64
RS1: Outcome Assessment in Pediatric Asthma: A Comparison of Symptom-Free Time and Multi-Attribute Scale
Chiou, C. F. / Weaver, M. R. / Bell, M. A. | 2001
64
MS4: A Systematic Review of Health State Values for Osteoporosis Related Conditions
Brazier, J. E. / Green, C. / Kanis, J. | 2001
64
S4: Methods for Comparing Areas Under Receiver Operating Characteristic Curves: Application in Screening Accuracy for Depression
Shaw, J. W. / Treglia, M. / Motheral, B. / Coons, S. J. | 2000
65
The Health Value and Cost of Care for Major Depression
Watkins, K. E. / Burnam, M. A. / Orlando, M. / Escarce, J. J. / Huskamp, H. A. / Goldman, H. H. | 2009
65
Use of Economic Evaluation in Decision Making: What Needs to Change?
Hutton, J. / Brown, R. E. | 2002
65
RS3: Psychometric Evaluation of the CAP-SYM Questionnaire: A New, Patient-Based Measure of Symptoms in Community Acquired Pneumonia
Lamping, D. / Schroter, S. / Sagnier, P. P. / Duprat-Lomon, I. | 2001
65
BT4: Cost-Effectiveness of High Versus Low Dose Angiotensin Converting Enzyme Inhibitors (ACEIs) in the Treatment of Chronic Heart Failure (CHF): An Economic Analysis of the US Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial
Schwartz, J. S. / Wang, Y. / Cleland, J. | 2000
65
Determinants of Health Economic Decisions in Actual Practice: The Role of Behavioral Economics
| 2006
65
RS2: Using Self-Administered Direct TTO Questions to Elicit Utility Values for Asthmatic Patients With Different Severity of Disease
Szende, A. / Meszaros, A. / Berta, G. Y. / Stahl, E. / Svensson, K. | 2001
65
BT3: The Comparative Economic Value of Raltitrexed and 5-FU Plus Leucovorin
Simons, W. R. / Grace, E. M. | 2000
65
RS4: A Model-Based Evaluation of Inhaled Steroids in Mild-To-Moderate Asthma
Paltiel, A. / Fuhlbrigge, A. / Kitch, B. / Weiss, S. / Neumann, P. / Kuntz, K. | 2001
65
Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System
Matter-Walstra, K. / Joerger, M. / K&#x00FC / hnel, U. / Szucs, T. / Pestalozzi, B. / Schwenkglenks, M. | 2012
66
A Quantitative Benefit-Risk Analysis of Isoniazid for Treatment of Latent Tuberculosis Infection Using Incremental Benefit Framework
Sadatsafavi, M. / Marra, C. / Marra, F. / Moran, O. / FitzGerald, J. M. / Lynd, L. | 2013
66
CEB5: Measuring Patient Preferences Using Conjoint Analysis: A New Approach
Phillips, K. A. / O'Brien, B. / Skolnik, H. / Johnson, T. R. | 2000
66
CEB7: Socioeconomic Efficiency of the Adjuvant Treatment with Acamprostate in Maintaining Abstinenance in Alcohol Dependent Patients
Kilburg, A. / Daniel, D. / Pfeil, T. / Kirchoff, D. / Rychilk, R. | 2000
66
CEB6: The IMportance of Comparable Patient Populations in Cost-Effectiveness Analyses: Tolterodine Versus Oxybutinin XL for Treating Overactive Bladder
Schonfeld, W. H. / Sheriff, S. K. / Levaux, H. P. / Williamson, T. E. | 2000
66
PAM2: An Economic Evaluation of Osteoporosis Medication Use Patterns in a Managed Care Organization: A Time to Fracture Analysis
Chen, K. S. / White, T. J. / Chang, E. | 2001
66
Do You Want to Hear the Bad News? The Value of Diagnostic Tests for Alzheimer’s Disease
Mühlbacher, A. / Johnson, F. R. / Yang, J. C. / Happich, M. / Belger, M. | 2016
66
PAM1: Joint Counts in Patients with New Onset Rheumatoid Arthritis: Patient vs. Physician Assessment
Kim, S. S. / Drabinski, A. M. / Williams, G. R. / Formica, C. A. | 2001
67
PCD1: Incorporating Both Diastolic and Systolic Pressures in a Model of the Benefits of Achieving Hypertension Treatment Targets
Huse, D. M. / Russell, M. W. / Usry, C. A. / Hartz, S. C. | 2000
67
Pediatricians’ Preferences for Infant Meningococcal Vaccination
Poulos, C. / Reed Johnson, F. / Krishnarajah, G. / Anonychuk, A. / Misurski, D. | 2015
67
CEB8: A Decision Analytic Model Measuring the Cost-Effectiveness of Highly Active Antiretroviral Therapy (HAART) in HIV + Patients with High Versus Low Baseline Viral Load: An Indinavir Plus Lamivudine and Zidovudine Example
Risebrough, N. A. / Oh, P. / Rachlis, A. / McMurchy, D. / Bast, M. / Doswell, M. | 2000
67
The Bias Against New Innovations in Health Care: Value Uncertainty and Willingness to Pay
Walton, S. M. / Graves, P. E. / Mueser, P. R. / Dow, J. K. | 2002
67
PAM4: Use of COX 2 NSAIDS in Subjects Without Risk of Gastrointestinal Side Effects
Harley, C. R. | 2001
67
PAM5: Investigating the Construct Validity of a Disease Specific and a General Quality of Life Instruments of Patients with Rheumatoid Arthritis
Lovas, K. / Szende, A. / Balint, G. / Szebenyi, B. / Hejj, G. | 2001
67
Pharmacoeconomics: Identifying the Issues Overview and Advisory Panel Report Summary
Gagnon, J. P. / Dix Smith, M. / Rindress, D. | 1999
67
Collection of Health-Economic Data Alongside Clinical Trials: Is There a Future for Piggyback Evaluations?
O'Sullivan, A. K. / Thompson, D. / Drummond, M. F. | 2005
67
PAM3: The Cost of Osteoporotic Fractures in the United Kingdom
Burge, R. T. / Worley, D. / Johansen, A. / Bose, U. | 2001
68
PAM6: Cost-Effectiveness of Rofecoxib Versus NSAIDs in the Treatment of Osteoarthritis
Sullivan, P. / Hay, J. | 2001
68
Cost-Effectiveness of Fondaparinux Compared with Enoxaparin as Prophylaxis against Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery
Sullivan, S. D. / Kwong, L. / Nutescu, E. | 2006
68
PCD2: Assessing the Burden of Illness in Elderly Versus Younger Acute Coronary Syndrome Patients
Eisenstein, E. L. / Peterson, E. D. / Shaw, L. K. / Hasselblad, V. / Nelson, C. L. / Hakim, Z. / Mark, D. B. | 2000
68
PAM7: The Correlation Between Arthritis Specific Measures and SF-36 Scales in Rheumatoid Arthritis Patients
Lubeck, D. P. / Yelin, E. / Katz, P. / Roepke, L. / Wanke, L. A. / Buatti, M. | 2001
68
PAM8: Cost Comparison of Treating Osteoporosis Patients with Estrogens or Selective Estrogen Receptor Modulator in a Managed Care Population
Liao, E. / Sweazy, L. / Huse, D. | 2001
68
PCD3: Incidence, Utilization of Health Care and Costs of Stroke
Wilson, L. / Le, K. / Nguyen, C. / Tam, A. / Le, S. | 2000
68
PCD4: The Impact of Secondary Events on the Cost of Acute Myocardial Infarction
O'Brien, J. / Pierce, D. / Caro, J. | 2000
69
Using a Discrete-Choice Experiment Involving Cost to Value a Classification System Measuring the Quality-of-Life Impact of Self-Management for Diabetes
Rowen, Donna / Stevens, Katherine / Labeit, Alexander / Elliott, Jackie / Mulhern, Brendan / Carlton, Jill / Basarir, Hasan / Ratcliffe, Julie / Brazier, John | 2018
69
Market Consolidation and Mortality in Patients Initiating Hemodialysis
Erickson, Kevin F. / Winkelmayer, Wolfgang C. / Ho, Vivian / Bhattacharya, Jay / Chertow, Glenn M. | 2019
69
PCD7: Socioeconomic Evaluation of Cilostazol for the Secondary Prevention of Cerebral Infarction in Japan
Kobayashi, M. / Gotah, F. | 2000
69
Budget Impact Analysis of Thrombolysis for Stroke in Spain: A Discrete Event Simulation Model
Mar, J. / Arrospide, A. / Comas, M. | 2010
69
PAM9: Cost Comparison of Treating Rheumatoid Arthritis Patients with COX-2 Inhibitors or NSAIDs in a Managed Care Population
Liao, E. / Kester, G. / Huse, D. | 2001
69
PAM10: The Impact of Early Rheumatoid Arthritis on Productivity
Kim, S. S. / Drabinski, A. M. / Williams, G. R. / Formica, C. A. | 2001
69
PCD6: Cost Analysis of Antihypertensive Drug Use in Turkey
Sapci, H. / Bozkurt, E. / Durlu, T. / Kandilci, B. / Ozsogut, B. / Demirdamar, R. / Akalin, K. / Mutlugil, A. | 2000
69
PCD5: Costs of Left Ventricular Assist Device Versus Positive Inotropic Therapy as a Bridge to Heart Transplant
Stanek, E. J. / Loh, E. | 2000
70
PCD9: Cost-Effectiveness of Ramipril in Hypertensive Patients with Nephropathy in Germany
Schadlich, P. K. / Brecht, J. G. / Huppertz, E. | 2000
70
Cost-Effectiveness versus Cost-Utility Analysis of Interventions for Cancer: Does Adjusting for Health-Related Quality of Life Really Matter?
Tengs, T. O. | 2004
70
PAM13: A Cost-Effectiveness Model Comparing Celecoxib and Rofecoxib to Traditional NSAIDs for Osteoarthritis Treatment
Schaefer, M. G. / Morreale, A. P. / Plowman, B. K. | 2001
70
From Translation to Version Management: A History and Review of Methods for the Cultural Adaptation of the EuroQol Five-Dimensional Questionnaire
Rabin, R. / Gudex, C. / Selai, C. / Herdman, M. | 2014
70
PCD10: Impact of New Statin Doses on Market Segmentation
Miller, J. D. / Russell, M. W. / Huse, D. M. / Hartz, S. C. | 2000
70
PAM12: Cost-Minimization Analysis of the Treatment of Rheumatoid Arthritis with Leflunomide in Comparison with the Combination of Infliximab and Methotrexate
Rubio-Terres, C. / Dominguez-Gil, A. | 2001
70
PAM11: Applying Background Risk Distribution to Evaluate the Cost-Effectiveness of Three Preventive Drug Therapies for Osteoporotic Fractures
Gao, X. / Madhavan, S. / Nau, D. / Ambegaonkar, A. / Islam, S. / Rosenbluth, S. / Amonkar, M. | 2001
70
The cost-utility analysis of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a probabilistic decision model
Uthman, O. A. / Popoola, T. A. / Yahaya, I. / Uthman, M. M. / Aremu, O. | 2011
70
PCD8: A Model Comparing Nitroglycerin Formulations for Acute Angina Episodes: Assessing the Economic Issues
Bell, C. F. / Semroc, G. N. / Stephens, J. M. / Klingman, D. / Dever, M. T. | 2000
71
Do Health-Care Decision Makers Find Economic Evaluations Useful? The Findings of Focus Group Research in UK Health Authorities
Hoffmann, C. / Stoykova, B. A. / Nixon, J. / Glanville, J. M. / Misso, K. / Drummond, M. F. | 2002
71
PAM16: Cost Impact of COX-2 Inhibitors in a Managed Care Plan: Implications for Formulary Decision-Making
Atherly, D. E. / Fullerton, D. S. / Sturm, L. L. / Bryant, A. / Sullivan, S. D. | 2001
71
PCD11: The Cost-Effectiveness Analysis as a Substantiation of Diagnostic and Treatment of Early Stage of Heart Failure
Gorokhova, S. G. / Vorobiev, P. A. | 2000
71
PAM15: Evaluating Direct and Indirect Measures of Utility: Stability of the SF-6D in a Rheumatoid Arthritis Population
Crawford, B. / Brazier, J. E. | 2001
71
PCD13: Cost-Effectiveness Analysis of Enalapril in the Management of CHF in Poland
Orlewska, E. / Kuzniar, J. / Romanczuk, W. / Splawinski, J. | 2000
71
PAM14: Treatment with Leflunomide Improves the Utility of Patients with Active Rheumatoid Arthritis: An Application of the SF-6D
Crawford, B. / Brazier, J. E. / Strand, V. / Doyle, J. | 2001
71
PCD12: Spironolactone in Heart Failure: Life and Cost Saving Treatment in Poland
Kuzniar, J. / Orlewska, E. / Splawinski, J. | 2000
72
PAM17: Important Issues in Number Needed to Treat Analysis in Osteoporosis Treatment
Kemner, J. E. | 2001
72
PAM18: Performance Assessment of Two Fatigue Instruments in an Early Rheumatoid Arthritis Cohort
Drabinski, A. / Kim, S. S. / Williams, G. / Formica, C. | 2001
72
PCD14: Treatment Cost of Side Effects of Antiarrhythmic Drugs in the USA
Bhattacharyya, S. K. / Morrato, E. H. | 2000
72
PCD15: How Meaningful Are the Coronary Benefits of Selective Estrogen Receptor Modulators?
Russell, M. W. / Huse, D. M. / Miller, J. D. / Hartz, S. C. | 2000
72
Clinical and Economic Outcomes Associated with Adjuvant Chemotherapy in Elderly Patients with Early Stage Operable Breast Cancer
Sail, K. R. / Franzini, L. / Lairson, D. R. / Du, X. L. | 2012
73
Using EQ-5D to Derive General Population-based Utilities for the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA):
Koltowska-Haggstrom, M. / Jonsson, B. / Isacson, D. / Bingefors, K. | 2007
73
Methodological Issues in Pharmacoeconomic Evaluations - Clinical Studies
Healey, M. / Deverka, P. | 1999
73
PCD17: The Effects of Payor Status on Procedure Use and Outcomes of Patients with Congestive Heart Failure
Kroch, E. / Loh, E. / Schwartz, J. S. / Shah, R. / Fisher, D. | 2000
73
PCD16: Cost-Effectiveness of Tirofiban Plus Heparin as Compared with Heparin Only in Treating Unstable Angina
Shi, L. / Hay, J. | 2000
73
PAM20: Cost-Effectiveness of Acetylcisteine and Dimethylsulphoxide (DMSO) 50% for the Treatment of Patients with Reflex Sympathic Dystrophy
van Dieten, H. E. / Perez, R. S. / Tulder, M. W. / Boers, M. / Zuurmond, W. W. / de Lange, J. J. / Vondeling, H. | 2001
73
PAM21: Manual Therapy is More Cost-Effective than Physical Therapy and GP Care for Patients with Neck Pain
Korthals-de Bos, I. B. / Hoving, J. / Tulder, M. / Bouter, L. | 2001
73
Gaining Efficiencies: Resources and Demand for Dialysis around the Globe
Neil, N. / Walker, D. R. / Sesso, R. / Blackburn, J. C. / Tschosik, E. A. / Sciaraffia, V. / Garcia-Contreras, F. / Capsa, D. / Bhattacharyya, S. K. | 2009
73
PAM19: A Review of Functional Status Measures for Workers with Upper Extremity Disorders
Salerno, D. F. / Copley-Merriman, C. / Taylor, T. N. / Shinogle, J. / Schulz, R. M. | 2001
73
PCD18: The Perceptual Effectiveness Index: A New Approach for Evaluating Outcomes of Anti-Hypertensive Therapy
Leidy, N. K. / Flynn, J. / Zyczynski, T. M. | 2000
74
PCD21: Two-Year Medication Compliance in Patients with Acute Myocardial Infarction
Plante, M. / Gupta, A. / Bruckman, D. / Mehta, R. / Eagle, K. | 2000
74
PCD20: Estimating the Effects of Polypharmacy on Hospitalization in an Elderly CHF Medicaid Population
Bramley, T. / Dickson, M. / Rowen, R. | 2000
74
PCD19: Relationship Between Daily Dose Frequency and Adherence to Antihypertensive Pharmacotherapy: Update of a Meta-Analysis
Iskedjian, M. / Einarson, T. R. | 2000
74
PAM22: Studying Predictors of Fractures Among Omnicare Nursing Home Residents
Oderda, G. M. / Gause, D. / Stuart, B. / Erwin, G. | 2001
74
PAM23: Vertebral Fractures Among Glucocorticoid Patients Significantly Increase Medical Care Costs
Meyer, J. W. / Burge, R. T. / Steinbuch, M. | 2001
75
PCD23: Unadjusted Inpatient Costs and Mortality for Four Cerebrovascular Events for Patients Treated at Community Teaching and Nonteaching Hospitals
Reed, S. D. / Jarvik, J. G. / Meyer, K. E. | 2000
75
Costs of Asthma in a Cohort of Swiss Adults: Associations with Exacerbation Status and Severity
Schwenkglenks, M. / Lowy, A. / Anderhub, H. / Szucs, T. D. | 2003
75
PAR2: Use of Respiratory Assist Devices by Medicare Beneficiaries
Silverman, B. G. | 2001
75
PAR1: Cost of Asthma in Children in Vladivostok
Prosekova, E. / Geltzer, B. / Dercach, V. / Bogdanovskiy, P. | 2001
75
The “Efficacy-Effectiveness Gap”: Historical Background and Current Conceptualization
Nordon, C. / Karcher, H. / Groenwold, R. H. / Ankarfeldt, M. Z. / Pichler, F. / Chevrou-Severac, H. / Rossignol, M. / Abbe, A. / Abenhaim, L. | 2016
75
PAR3: The Standardized Asthma-Related Quality of Life Questionnaire (AQLQ-S): Does Socioeconomic Status Effect Measurements?
Lynd, L. D. / Guh, D. / Pare, P. / Anis, A. | 2001
75
PCD22: The Effect of Nationality on Health-Related Quality of Life in the Gusto-I Angiographic Trial
Coyne, K. / Hill, M. / Allen, J. / Kim, M. / Chandra, N. / Ross, A. | 2000
76
PCD25: Systematic Review Evidence on Treating Hypertension in Older Adults
McDonagh, M. / Bradley, M. / Shirley, A. / Kleijnen, J. | 2000
76
PCD24: Conjoint Analysis Comparing Preferences for Treatment Outcomes in Heart Failure and Healthy Patients: Longevity Versus Symptom Relief
Oates, M. B. / Stanek, E. J. / McGhan, W. F. / DeNofrio, D. / Loh, E. | 2000
76
PAR5: Direct and Indirect Costs of Respiratory Infections
Birnbaum, H. G. / Morley, M. A. / Greenberg, P. E. / Cifaldi, M. / Colice, G. L. | 2001
76
Health State Utilities: A Framework for Studying the Gap Between the Imagined and the Real
Stiggelbout, A. M. / de Vogel-Voogt, E. | 2008
76
Core Domains for a Person-Focused Outcome Measurement System in Cancer (PROMS-Cancer Core) for Routine Care: A Scoping Review and Canadian Delphi Consensus
Howell, D. / Fitch, M. / Bakker, D. / Green, E. / Sussman, J. / Mayo, S. / Mohammed, S. / Lee, C. / Doran, D. | 2013
76
PCD26: A Closer Look at Hypertension Practice Patterns and Medication Compliance
Guico-Pabia, C. J. / Campbell, R. F. / Dedeker, K. / Sheffeld, R. / Moravec, R. / Wertheimer, A. L. | 2000
76
PAR4: Comparison of Two Quality of Life Instruments in Patients with Chronic Obstructive Pulmonary Disease
Aubert, R. E. / Alemayehu, B. / Feifer, R. | 2001
77
PAR6: Prophylactic Medication Utilization and Health Care Costs in Older Adults with Chronic Pulmonary Ailments
Balkrishnan, R. / Christensen, D. / Bowton, D. | 2001
77
PMH1: Recent Trends in the Cost of Care for Patients with Schizophrenia
Johnstone, B. M. / Loosbrock, D. L. / Stockwell Morris, L. / Gibson, J. P. / Barber, B. L. / Lichtenstein, M. / Henderson, S. / Dulisse, B. K. | 2000
77
PAR7: Validation of a Model of Severity of Illness in Chronic Respiratory Disease
Sullivan, P. / Nichol, M. | 2001
77
PAR8: A Cost-Effectiveness Analysis Comparing Levalbuterol and Albuterol in the Treatment of Moderate to Severe Asthma
Carter, C. T. / McGee, M. D. | 2001
77
Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial
Tunis, S. L. / Faries, D. E. / Nyhuis, A. W. / Kinon, B. J. / Ascher-Svanum, H. / Aquila, R. | 2006
77
PMH2: Estimated Costs of Treatment for Bipolar Affective Disorder in a Large Employer Database
Johnstone, B. M. / Loosbrock, D. L. / Stockwell Morris, L. / Gibson, J. P. / Barber, B. L. / Lichtenstein, M. / Henderson, S. / Dulisse, B. K. | 2000
77
Identifying Patients With Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Healthcare Data
Van Le, Hoa / Le Truong, Chi Thi / Kamauu, Aaron W.C. / Holmén, John / Fillmore, Christopher / Kobayashi, Monica G. / Martin, Canter / Sabidó, Meritxell / Wong, Schiffon L. | 2019
77
Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors and Cost Implications of Immunoprophylaxis to Infants 32 to 35 Weeks Gestation for Health Plans in the United States
Krilov, L. R. / Palazzi, D. L. / Fernandes, A. W. / Klein, R. W. / Mahadevia, P. J. | 2010
77
Health Utility Scores in Alzheimer’s Disease: Differences Based on Calculation With American and Canadian Preference Weights
Oremus, M. / Tarride, J. E. / Clayton, N. / Raina, P. | 2014
78
PMH4: Antipsychotic Medication Treatment Patterns and Associated Cost of Care of Patients with Schizophrenia
Loosbrock, D. L. / Johnstone, B. M. / Stockwell Morris, L. / Gibson, P. J. / Barber, B. L. / Lichtenstein, M. S. / Henderson, S. C. / Dulisse, B. K. | 2000
78
PMH3: Alzheimer's Disease Cost of Care in Managed Care
Richards, K. M. / Shepherd, M. D. / Crismon, M. L. / Snyder, E. H. | 2000
78
Methodological Issues in Conducting Pharmacoeconomic Evaluations - Modeling Studies
Hay, J. / Jackson, J. | 1999
78
PAR11: The Long-Term Societal Economic and Humanistic Benefits of Treating Acute Exacerbations of Chronic Bronchitis (AECB) with Gemifloxacin Versus Clarithromycin
Halpern, M. / Kirsch, J. M. / Palmer, C. / Zodet, M. / Wilson, R. | 2001
78
PAR10: Implementing Rasch Analysis in Psychometric Evaluation of Patient-Physician Interaction Scale
Dalal, M. / Smith, E. / Lambert, B. / Olopade, C. / Crawford, S. | 2001
78
Physicians’ Preferences for Bone Metastases Drug Therapy in the United States
Arellano, J. / Hauber, A. B. / Mohamed, A. F. / Gonzalez, J. M. / Collins, H. / Hechmati, G. / Gatta, F. / Qian, Y. | 2015
78
PAR9: Validation of a Rating Instrument Assessing the Inhalation Skills of Children with Asthma
Pradel, F. G. / Weiss, S. / Tsoukleris, M. / Bollinger, M. B. / Fahlman, C. | 2001
78
Women’s Benefits and Harms Trade-Offs in Breast Cancer Screening: Results from a Discrete-Choice Experiment
Sicsic, Jonathan / Pelletier-Fleury, Nathalie / Moumjid, Nora | 2018
79
PMH6: Pharmacoeconomic Analyses of Depot Neuroleptic Treatment in Natural Setting
Gurovich, I. / Kobina, S. / Lyubov, E. / Litvischenko, Y. / Shmukler, A. | 2000
79
Assessment of Health-Related Quality of Life in Children: A Review of Conceptual, Methodological, and Regulatory Issues
Matza, L. S. / Swensen, A. R. / Flood, E. M. / Secnik, K. / Leidy, N. K. | 2004
79
PMH5: The Effect of Rivastigmine on the Direct and Indirect Costs of Alzheimer's Disease
Brooks, E. / Deal, L. | 2000
79
Is Sepsis Accurately Coded on Hospital Bills?
Ollendorf, D. A. / Fendrick, A. M. / Massey, K. / Williams, G. R. / Oster, G. | 2002
79
PAR12: Prospective Use of Web Based Technology to Evaluate Health Outcomes in a Large Cohort of Severe or Difficult to Treat Asthmatics
Dolan, C. M. / Fisher, K. A. / Johnson, C. / Fraher, K. E. / Rothermich, E. A. / Fine, J. T. / Weiss, S. T. / Wenzel, S. | 2001
79
PAR13: Hypothetical Versus Real Willingness to Pay in the Health Care Sector: Results from a Field Experiment
Blumenschein, K. / Johannesson, M. / Yokoyama, K. / Freeman, P. | 2001
79
PMH7: Cost-Effectiveness of Atypical Antipsychotics in Chronic Schizophrenia
Karki, S. D. / Bellnier, T. J. / Hager, E. P. | 2000
80
PAR16: Cost of Treating Asthma in a Managed Care Population
Armstrong, E. P. / Malone, D. C. / Rehfeld, R. A. | 2001
80
PAR15: Comparison of Health Care Resource Utilization of COPD Patients on Cilomilast, 15 mg BID Versus Placebo
Bagchi, I. / Bakst, A. / Edelson, J. / Amit, O. | 2001
80
PMH8: Cost-Effectiveness of Stratified Care in the Management of Migraine
Rapoport, A. / Lipton, R. B. / Williams, P. / Sawyer, J. | 2000
80
Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy
Iannazzo, S. / Pradelli, L. / Carsi, M. / Perachino, M. | 2011
80
PMH10: A Model to Perform Economic Evaluations of Interventions for Acute Muscular Low Back Pain
Neighbors, D. / Earnshaw, S. R. / Bell, L. / Bhattacharyya, S. K. | 2000
80
PAR14: Assessment of the Relationship Between Disease Severity, Quality of Life and Willingness to Pay in Asthma
Zillich, A. / Blumenschein, K. / Johannesson, M. / Freeman, P. | 2001
80
Some Considerations for the Interpretation of Health-Related Quality of Life Data
| 2005
80
PMH9: A Managed Care Validation Program for a Pharmacoeconomic Model of Major Depression
Casciano, J. / Arikian, S. / Doyle, J. J. / Casciano, R. | 2000
80
An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard
Lee, C. P. / Chertow, G. M. / Zenios, S. A. | 2009
81
PAR18: Costs of Treating COPD in Italy: A Burden of Illness Study
Bonzanini, A. / Avossa, R. / Scipioni, E. / Gianfrate, F. | 2001
81
PMH12: The Efficiency of Drug Treatment in First Episode Schizophrenia: Treatment Guidelines in the UK
Davies, L. M. / Lewis, S. | 2000
81
PAR19: Impact of the Addition of Salmeterol to the Treatment of Asthma Patients in a Medicaid Fee-for-Service Population
Klaurens, L. M. / Dodd, M. A. / Gupchup, G. V. / Kelly, H. W. / Hollarbush, J. | 2001
81
Direct Cost Analysis of Intensive Care Unit Stay in Four European Countries: Applying a Standardized Costing Methodology
Tan, S. S. / Bakker, J. / Hoogendoorn, M. E. / Kapila, A. / Martin, J. / Pezzi, A. / Pittoni, G. / Spronk, P. E. / Welte, R. / Hakkaart-van Roijen, L. | 2012
81
PMH11: Treatment Guidelines Compared to Clinical Practice for Acute Muscular Low Back Pain
Earnshaw, S. R. / Neighbors, D. / Bell, L. / Bhattacharyya, S. K. | 2000
81
PAR17: Patient Satisfaction with Non-Sedating Antihistamines
Sahu, S. / Millard, R. | 2001
82
PMH14: Use of Olanzapine and Risperidone at Baseline in a Prospective Study of the Course of Treatment for Schizophrenia
Johnstone, B. M. / Dulisse, B. K. / Loosbrock, D. L. / Gibson, P. J. | 2000
82
Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients
Brenner, B. / Geva, R. / Rothney, M. / Beny, A. / Dror, Y. / Steiner, M. / Hubert, A. / Idelevich, E. / Gluzman, A. / Purim, O. | 2016
82
Development of a Decision-Analytic Model of Stroke Care in the United States and Europe
Chambers, M. G. / Koch, P. / Hutton, J. | 2002
82
PMH13: Withdrawn
| 2000
82
Needs-Based Health-Related Quality of Life Measurement: New Wine in Old Bottles?
| 2005
82
PAR20: Effectiveness of Compliance on Health Care Resource Use in Asthma Patients Treated with Montelukast vs. Inhaled Corticosteroids
Kutikova, L. / Bowman, L. / Morris, L. | 2001
82
Methodological Issues in Conducting Pharmacoeconomic Evaluations - Retrospective and Claims Database Studies
Goldberg Arnold, R. / Kotsanos, J. G. | 1999
82
PAR21: Levalbuterol Use is Associated with Decreased Health Care Costs in Patients with More Severe Asthma
Huse, D. / McLoney, A. / Yeager, B. / Cerasoli, F. | 2001
82
PMH15: Utilization of Antipsychotic Medications in the Treatment of Schizophrenia in a Managed Care Population
Nichol, M. B. / Harada, A. S. M. / Jones, J. P. / McCombs, J. S. / Grogg, A. / Gilderman, A. / Vaccaro, J. | 2000
83
PMH16: Use of Atypical Antipsychotic Medications in a Veterans Population
Hudson, T. / Feng, W. / Owen, R. / Austen, M. | 2000
83
The Cost-Effectiveness of Expanding Newborn Screening for up to 21 Inherited Metabolic Disorders Using Tandem Mass Spectrometry: Results from a Decision-Analytic Model
Cipriano, L. E. / Rupar, C. A. / Zaric, G. S. | 2007
83
PMH18: Use of Nonbarbiturate Sedative/Hypnotic Agents in an Ambulatory Population
Hornquist, M. / Carlson, A. / Morris, L. | 2000
83
PAR23: Determinants of Inappropriate Antibiotic Prescribing
Willis, M. K. | 2001
83
PMH17: Bipolar Disorder Drug Use Patterns and Compliance in Medi-Cal Population
Li, J. / McCombs, J. / Stimmel, G. | 2000
83
PAR22: Impact of Levalbuterol Versus Racemic Albuterol on Outpatient Asthma Care Charges
Huse, D. / McLoney, A. / Yeager, B. / Cerasoli, F. | 2001
Feedback